Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ark Therapeutics applies for gene technology patent

Ark Therapeutics applies for gene technology patent

26th February 2009

Ark Therapeutics has applied for a technique that can both silence and increase DNA expression within a cell to be patented, it has been reported.

The submission of approval is for the firm’s RNA technology, which allows both up and down regulation of a multiple genetic material and builds on the company’s existing gene knowledge, explained Reuters.

Current remedies tend to only work by suppressing the effect of certain DNA.

However, this latest development can work on genes that are either overactive or do not work at all.

The discovery has the potential to be used in creating treatments for a number of human diseases caused by defective genetic material, the news agency concluded.

Specialist healthcare group Ark Therapeutics has operations in the UK and Finland.

Areas it concentrates its developments on include wound care, cancer and vascular disease.

The Financial Times reported earlier this month that the French authorities had approved the use of the company’s drug Cerepro for the treatment of brain cancer.

After this decision, shares in the firm rose from 2.3 pence to 45 pence, the newspaper added.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.